title: [Therapeutic effects of epimeric glycyrrhizic acids on hepatic injury in rats].
abstract: The effects of the epimeric glycyrrhizic acids (GA), 18 alpha-form and 18 beta-form, on D-galactosamine (Gal)-induced acute liver injury and fulminating hepatic failure (FHF) in rats were studied. In rats of acute liver injury, extensive liver parenchymal cell damage was observed by the elevation of alanine aminotransferase (ALT) activity and confirmed by significant histopathological changes 24 and 48 h after ip Gal 450 mg.kg-1. Moreover, marked elevation in the liver putrescine levels occurred along with that of serum ALT. The spermidine and spermine levels did not alter significantly. GA 18 alpha-form 300 mg.kg-1 ip suppressed the elevation of serum ALT and liver putrescine levels, and improved all the histopathologic features. On the other hand, GA 18 beta-form 300 mg.kg-1, which exhibited inhibitory effects 24 h after ip Gal, showed no action 48 h after ip Gal. The ALT levels in the serum from GA 18 alpha-form, 18 beta-form, vs control groups after 24 h were 70 +/- 24 (P < 0.01) and 78 +/- 42 (P < 0.01) vs 155 +/- 57, and after 48 h were 74 +/- 25 (P < 0.01) and 258 +/- 99 (P > 0.05) vs 293 +/- 110. The putrescine contents (nmol.g-1) in the liver from GA 18 alpha-form, 18 beta-form, vs control after 24 h were 34 +/- 9 (P < 0.01) and 51 +/- 12 (P < 0.01) vs 139 +/- 29, and after 48 h were 16 +/- 3 (P < 0.01) and 150 +/- 11 (P > 0.05) vs 156 +/- 23.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Clinical Pharmacology, Hangzhou Sixth Hospital, China.
authors.forename: X M
authors.initials: XM
authors.lastname: Wu
authors.forename: J
authors.initials: J
authors.lastname: Lu
authors.forename: B R
authors.initials: BR
authors.lastname: Li
authors.forename: B G
authors.initials: BG
authors.lastname: Zhang
authors.forename: R P
authors.initials: RP
authors.lastname: Ru
mesh_terms: D000410:Alanine Transaminase / Q000097:blood; D000818:Animals; D056486:Chemical and Drug Induced Liver Injury / Q000188:drug therapy* / Q000209:etiology / Q000378:metabolism; D005688:Galactosamine; D006034:Glycyrrhetinic Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use; D019695:Glycyrrhizic Acid; D017093:Liver Failure / Q000188:drug therapy / Q000473:pathology; D008297:Male; D011700:Putrescine / Q000378:metabolism; D051381:Rats; D017208:Rats, Wistar; D013237:Stereoisomerism; D013329:Structure-Activity Relationship
chemical_list: D019695:Glycyrrhizic Acid; D005688:Galactosamine; D000410:Alanine Transaminase; D006034:Glycyrrhetinic Acid; D011700:Putrescine